<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="815">
  <stage>Registered</stage>
  <submitdate>12/09/2005</submitdate>
  <approvaldate>12/09/2005</approvaldate>
  <nctid>NCT00190892</nctid>
  <trial_identification>
    <studytitle>Olanzapine Plus Carbamazepine in the Treatment of Bipolar I Mania</studytitle>
    <scientifictitle>Olanzapine Plus Carbamazepine Versus Carbamazepine Alone in the Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>F1D-MC-HGKR</secondaryid>
    <secondaryid>7031</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Bipolar Disorder</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Other mental health disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Depression</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - olanzapine
Treatment: drugs - carbamazepine

Treatment: drugs: olanzapine


Treatment: drugs: carbamazepine


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To assess the superiority of olanzapine plus carbamazepine versus placebo plus carbamazepine in improving overall manic symptomatology in patients with mania associated with bipolar I disorder.</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Improvement is measured by a reduction in the total score of the Young Mania Rating Scale (YMRS) from baseline to endpoint during the 6-week, double-blind treatment phase.</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To compare the efficacy and safety of up to 6 weeks of double-blind, concomitant use of olanzapine plus carbamazepine to the concomitant use of placebo plus carbamazepine</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Using the following assessments:</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>rate of response and time to response over 6 weeks of the double-blind treatment phase, with response defined as a reduction of 50% or more in the YMRS total score from baseline to endpoint.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>rate of remission and time to remission of mania over 6 weeks of the double-blind treatment phase, with remission defined as a score less than or equal to 12 on the YMRS total score at endpoint</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>reductions from baseline to the endpoint of the 6-week, double-blind treatment phase on the Montgomery-Asberg Depression Rating Scale (MADRS) total score</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>reductions from baseline to the endpoint of the 6-week, double-blind treatment phase on the Clinical Global Impressions-Bipolar Version Severity of Illness Scale (CGI-BP)score</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>rate of switch to depression and time to switch to depression, with switch to depression defined as a baseline MADRS total score less than or equal to 12 followed by</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>either a post baseline MADRS total score greater than or equal to 16 over the 6 weeks of the double-blind treatment phase OR, hospitalization due to deterioration in clinical</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>symptoms of depression</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>longitudinal effects from baseline across visits of the double-blind treatment phase by comparing changes in YMRS total scores</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>changes in vital signs and weight, laboratory analytes, and electrocardiograms (ECGs), and the incidence and severity of TEAEs and extrapyramidal symptoms (EPS)</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>using the Barnes Akathisia Scale, Simpson-Angus Scale and the AIMS.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>the effect of carbamazepine on the plasma concentration of olanzapine via comparison to historic oral steady-state olanzapine concentrations</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>the effect of olanzapine on the plasma concentrations of carbamazepine via a descriptive comparison of the two treatment groups</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Additional secondary objectives are to assess the maintenance of treatment effect and safety of up to 20 weeks of open-label olanzapine-plus-carbamazepine treatment</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>using the following measures:</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>YMRS total score change from the baseline (Visit 7) to the endpoint of the open-label treatment phase.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>rate of relapse to mania during the open-label treatment phase. Relapse to mania (patients who relapse to a bipolar I mania or mixed episode) is defined by the following:</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>patient reaches remission of mania (as defined by a YMRS score less than or equal to 12) by the endpoint of the double-blind treatment phase</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>patient obtains a YMRS score greater than or equal to 15 at any time during the open label treatment phase AND/OR becomes hospitalized due to deterioration in clinical symptoms of mania</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>rate of switch to depression during open-label treatment phase, with switch to depression defined as a baseline MADRS total score less than or equal to 12 followed by</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>either a postbaseline MADRS total score greater than or equal to 16 over the 20 weeks of the open-label treatment phase hospitalization due to deterioration in clinical symptoms of depression</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>changes in vital signs and weight, laboratory analytes, and ECGs, and the incidence and severity of TEAEs and EPS using the Barnes Akathisia Scale, Simpson-Angus Scale, and the Abnormal Involuntary Movement Scale (AIMS)</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Have a diagnosis of bipolar disorder and currently meet DSM-IV-TR criteria for a manic
             or mixed episode

          2. Female patients must test negative on a serum pregnancy test at the time of enrollment
             and agree to use medically accepted contraception throughout the study.

          3. Have YMRS score &gt; or = 20 at both the screening (Visit 1) and randomization (Visit 2)
             visits.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Have participated (been randomized) in a clinical trial of another investigational
             drug (including olanzapine or carbamazepine) within 30 days prior to Visit 1

          2. Have a history of agranulocytosis (absolute neutrophil count&lt; 500/uL) during the
             patient's lifetime

          3. Have acute, serious or unstable medical conditions, including (but not limited to)
             inadequately controlled diabetes (HgbA1c&gt;8%); severe hypertriglyceridemia (fasting
             triglycerides &gt; or = 500 mg/dl;hepatic insufficiency (specifically any degree of
             jaundice); recent cerebrovascular accidents; uncontrolled seizure disorders; serious
             acute systemic infection or immunologic disease: unstable cardiovascular disorders
             (including ischemic heart disease); or renal, gastroenterologic, respiratory,
             endocrinologic, neurologic, or hematologic diseases (specifically current absolute
             neutrophil count , &lt;1500/uL)

          4. Have a substance dependence (except nicotine or caffeine), based on DSM-IV-TR
             criteria, within the 30 days prior to study entry.

          5. Require concomitant treatment with any other medication with primarily central nervous
             system (CNS) activity, other than those allowed in the protocol.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2004</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD,VIC</recruitmentstate>
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician - Everton Park</hospital>
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician - Epping</hospital>
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician - Frankston</hospital>
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician - Malvern</hospital>
    <postcode> - Everton Park</postcode>
    <postcode> - Epping</postcode>
    <postcode> - Frankston</postcode>
    <postcode> - Malvern</postcode>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Corfu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Kavala</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Tripoli</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Debrecen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Gyula</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Szekesfehervar</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>St. Petersburg</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Eli Lilly and Company</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This trial will assess any efficacious benefit and any safety issues associated with the
      concomitant use of olanzapine and carbamazepine for the treatment of patients with bipolar I
      disorder, manic or mixed episodes</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00190892</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)</name>
      <address>Eli Lilly and Company</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>